HIV-1 subtypes B and C Tat differentially impact synaptic plasticity expression and implicates HIV associated neurocognitive disorders

Current HIV Research

Volumn 12, Issue 6, 2014, Pages 397-405

  Samikkannu, Thangavel ^a   Atluri, Venkata S R ^a   Arias, Adriana Y ^a   Rao, Kesava V K ^a   Mulet, Carmen T ^a   Jayant, Rahul D ^a   Nair, Madhavan P N ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

HIV subtypes; SK N MC; Synaptic plasticity; Tat

Indexed keywords

GLUTAMATE AMMONIA LIGASE; TRANSACTIVATOR PROTEIN;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENDRITE; DNA SYNTHESIS; EXTRACELLULAR MATRIX; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NERVE CELL PLASTICITY; NEUROBLASTOMA CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RNA ISOLATION; GENE EXPRESSION PROFILING; HOST PATHOGEN INTERACTION; METABOLISM; NERVE CELL; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; NEURONAL PLASTICITY; NEURONS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84931041313     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162x13666150121104720     Document Type: Article

References (53)

1. [1] Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005; 5(1): 69-81.
2. [2] Antinori A, Trotta MP, Lorenzini P, et al. Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation. Antivir Ther. 2007; 12(8): 1175-83.
3. [3] Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007; 8(1): 33-44.
4. [4] McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? Aids. 2010; 24(9): 1367-70.
5. [5] Nath A, Psooy K, Martin C, et al. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol. 1996; 70(3): 1475-80.
6. [6] Amarapal P, Tantivanich S, Balachandra K, et al. The role of the Tat gene in the pathogenesis of HIV infection. Southeast Asian J Trop Med Public Health. 2005; 36(2): 352-61.
7. [7] Jiang ZG, Piggee C, Heyes MP, et al. Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages. Journal of Neuroimmunology. 2001; 117(12): 97-107.
8. [8] Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis. 2002; 186 Suppl 2: S193-8.
9. [9] Eugenin EA, King JE, Nath A, et al. HIV-tat induces formation of an LRP-PSD-95-NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci USA. 2007; 104(9): 3438-43.
10. [10] Carey AN, Sypek EI, Singh HD, Kaufman MJ, McLaughlin JP. Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behavioural Brain Research. 2012; 229(1): 48-56.
11. [11] Fitting S, Ignatowska-Jankowska BM, Bull C, et al. Synaptic Dysfunction in the Hippocampus Accompanies Learning and Memory Deficits in Human Immunodeficiency Virus Type-1 Tat Transgenic Mice. Biological Psychiatry. 2013; 73(5): 443-53.
12. [12] Kim HJ, Martemyanov KA, Thayer SA. Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. J Neurosci. 2008; 28(48): 12604-13.
13. [13] Chandra T, Maier W, Konig HG, et al. Molecular interactions of the type 1 human immunodeficiency virus transregulatory protein Tat with N-methyl-d-aspartate receptor subunits. Neuroscience. 2005; 134(1): 145-53.
14. [14] Haughey NJ, Mattson MP. Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J Acquir Immune Defic Syndr. 2002; 31 Suppl 2: S55-61.
15. [15] Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. Science. 2000; 288(5463): 55-6.
16. [16] Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr. 2002; 29(2): 184-90.
17. [17] Korber B KC, Foley B, et al. Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory. 1998.
18. [18] Rambaut A, Robertson DL, Pybus OG, Peeters M, Holmes EC. Human immunodeficiency virus: Phylogeny and the origin of HIV-1. Nature. 2001; 410(6832): 1047-8.
19. [19] Myers G, MacInnes K, Korber B. The emergence of simian/human immunodeficiency viruses. AIDS Res Hum Retroviruses. 1992; 8(3): 373-86.
20. [20] Mishra M, Vetrivel S, Siddappa NB, Ranga U, Seth P. Cladespecific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol. 2008; 63(3): 366-76.
21. [21] Campbell GR, Watkins JD, Singh KK, Loret EP, Spector SA. Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol. 2007; 81(11): 5919-28.
22. [22] Samikkannu T, Rao KV, Pilakka Kanthikeel S, Subba Rao Atluri V, Agudelo M, Roy U, et al. Immunoneuropathogenesis of HIV-1 clades B and C: Role of redox expression and thiol modification. Free Radic Biol Med. 2014; 69: 136-44.
23. [23] Samikkannu T, Agudelo M, Gandhi N, et al. Human immunodeficiency virus type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS. Journal of NeuroVirology. 2011; 17(3): 230-8.
24. [24] Atluri VS, Kanthikeel SP, Reddy PV, Yndart A, Nair MP. Human synaptic plasticity gene expression profile and dendritic spine density changes in HIV-infected human CNS cells: role in HIVassociated neurocognitive disorders (HAND). PLoS One. 2013; 8(4): e61399.
25. [25] Kurapati KR, Atluri VS, Samikkannu T, Nair MP. Ashwagandha (Withania somnifera) reverses beta-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND). PLoS One. 2013; 8(10): e77624.
26. Draghici S. Statistical intelligence: effective analysis of high density microarray data. Drug Discov Today. 2002; 7(S55-S63).
27. [27] Souba WW. Glutamine: Physiology, Biochemistry and Nutrition in Critical Illness (Medical Intelligence Unit). Co RGL, editor. Austin, TX 1992.
28. [28] Samikkannu MPNNAT. Differential Regulation of Neurotoxin in HIV Clades: Role of Cocaine and Methamphetamine. Current HIV Research. 2012; 10(5): 429-34.
29. [29] Samikkannu T, Rao KK, Gandhi N, Saxena S, Nair MN. Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS. Journal of NeuroVirology. 2010; 16(4): 255-63.
30. [30] Samikkannu T, Saiyed ZM, Rao KVK, et al. Differential Regulation of Indoleamine-2,3-Dioxygenase (IDO) by HIV Type 1 Clade B and C Tat Protein. AIDS Research and Human Retroviruses. 2009; 25(3): 329-35.
31. [31] Atluri VS, Pilakka-Kanthikeel S, Samikkannu T, et al. Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder. Mol Brain. 2014; 7: 37.
32. [32] Schoepp DD. Unveiling the Functions of Presynaptic Metabotropic Glutamate Receptors in the Central Nervous System. Journal of Pharmacology and Experimental Therapeutics. 2001; 299(1): 12-20.
33. [33] Bhardwaj A, Northington FJ, Martin LJ, Hanley DF, Traystman RJ, Koehler RC. Characterization of Metabotropic Glutamate Receptor-Mediated Nitric Oxide Production In Vivo. J Cereb Blood Flow Metab. 1997; 17(2): 153-60.
34. [34] Qiang M, Rani CSS, Ticku MK. Neuron-Restrictive Silencer Factor Regulates the N-Methyl-d-aspartate Receptor 2B Subunit Gene in Basal and Ethanol-Induced Gene Expression in Fetal Cortical Neurons. Molecular Pharmacology. 2005; 67(6): 2115-25.
35. [35] Shih AY, Johnson DA, Wong G, et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci. 2003; 23(8): 3394-406.
36. [36] Krogh KA, Wydeven N, Wickman K, Thayer SA. HIV-1 protein Tat produces biphasic changes in NMDA-evoked increases in intracellular Ca2+ concentration via activation of Src kinase and nitric oxide signaling pathways. J Neurochem. 2014; 130(5): 642-56.
37. [37] Liu X, Jana M, Dasgupta S, et al. Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia. J Biol Chem. 2002; 277(42): 39312-9.
38. [38] Holscher C. Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity. Trends Neurosci. 1997; 20(7): 298-303.
39. [39] Prast H, Philippu A. Nitric oxide as modulator of neuronal function. Progress in Neurobiology. 2001; 64(1): 51-68.
40. [40] Lipton SA, Choi Y-B, Pan Z-H, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 1993; 364(6438): 626-32.
41. [41] Choi S, Klingauf J, Tsien RW. Postfusional regulation of cleft glutamate concentration during LTP at /`silent synapses/'. Nat Neurosci. 2000; 3(4): 330-6.
42. [42] Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol. 2001; 3(2): 193-7.
43. [43] Pocernich CB, Sultana R, Mohmmad-Abdul H, Nath A, Butterfield DA. HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Research Reviews. 2005; 50(1): 14-26.
44. [44] Pinard A, Robitaille R. Nitric oxide dependence of glutamatemediated modulation at a vertebrate neuromuscular junction. European Journal of Neuroscience. 2008; 28(3): 577-87.
45. [45] Vincent VRAM, De Groot CJA, Lucassen PJ, et al. Nitric oxide synthase expression and apoptotic cell death in brains of AIDS and AIDS dementia patients. Aids. 1999; 13(3): 317-26.
46. [46] Satishchandra P, Nalini A, Gourie-Devi M, et al. Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989-96). Indian J Med Res. 2000; 111: 14-23.
47. [47] Gee CE, Peterlik D, Neuhauser C, et al. Blocking Metabotropic Glutamate Receptor Subtype 7 (mGlu7) via the Venus Flytrap Domain (VFTD) Inhibits Amygdala Plasticity, Stress, and Anxietyrelated Behavior. Journal of Biological Chemistry. 2014; 289(16): 10975-87.
48. [48] Zhou J, Du W, Zhou K, et al. Critical role of TRPC6 channels in the formation of excitatory synapses. Nat Neurosci. 2008; 11(7): 741-3.
49. [49] Pingle SC, Jajoo S, Mukherjea D, et al. Activation of the adenosine A1 receptor inhibits HIV-1 tat-induced apoptosis by reducing nuclear factor-kappaB activation and inducible nitric-oxide synthase. Mol Pharmacol. 2007; 72(4): 856-67.
50. [50] Sawaya BE, Thatikunta P, Denisova L, et al. Regulation of TNFalpha and TGFbeta-1 gene transcription by HIV-1 Tat in CNS cells. J Neuroimmunol. 1998; 87(1-2): 33-42.
51. [51] Patel S, Hamill TG, Connolly B, et al. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nuclear Medicine and Biology. 2007; 34(8): 1009-17.
52. [52] Nutt S, Kamboj R. Differential RNA editing efficiency of AMPA receptor subunit GluR-2 in human brain. Neuroreport. 1994; 5: 1679-83.
53. [53] Liu SJ, Zukin RS. Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends in Neurosciences. 2007; 30(3): 126-34.